Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

A Phase 1 Study of ADI-001 in Lupus Nephritis

Phase 1

Recruiting

Conditions: Lupus Nephritis
Autoimmune Diseases

Interventions: Drug: ADI-001
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-04-19

Last Posted Date: 2024-10-31

Lead Sponsor: Adicet Therapeutics

Target Recruit Count: 40

Registration Number: NCT06375993

Locations: 🇺🇸
The Feinstein Institutes for Medical Research - Northwell Health, Manhasset, New York, United States

A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus

Phase 1

Not yet recruiting

Conditions: Lupus Erythematosus, Systemic

Interventions: Biological: ATHENA CAR-T
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-04-18

Last Posted Date: 2024-06-17

Lead Sponsor: EdiGene Inc.

Target Recruit Count: 12

Registration Number: NCT06373991

Locations: 🇨🇳
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China

Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

Phase 2

Not yet recruiting

Conditions: Relapsed or Refractory Acute Lymphoblastic Leukemia

Interventions: Biological: ssCART-19
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-04-16

Last Posted Date: 2024-04-19

Lead Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Target Recruit Count: 50

Registration Number: NCT06367114

Locations: 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, China
🇨🇳
Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd., Shanghai, Shanghai, China

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Phase 1

Recruiting

Conditions: B-Cell Chronic Lymphocytic Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
B-Lymphocytic Leukemia, Chronic

Interventions: Biological: Autologous HuCD19 ( Anti-CD19)CAR T cells
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2024-04-15

Last Posted Date: 2024-12-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT06364423

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Phase 1

Recruiting

Conditions: Minimal Residual Disease
Colorectal Cancer

Interventions: Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Drug: Cetuximab
Drug: TROP2-CAR-NK Cells
Drug: Rimiducid (AP1903)
Procedure: Lymphodepleting Chemotherapy

First Posted Date: 2024-04-10

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT06358430

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Phase 1

Recruiting

Conditions: Relapse
Resistant Cancer
Breast Cancer
Triple Negative Breast Cancer

Interventions: Biological: iC9-CAR.B7-H3 T Cell Therapy
Drug: cyclophosphamide
Drug: fludarabine

First Posted Date: 2024-04-04

Last Posted Date: 2024-10-26

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 42

Registration Number: NCT06347068

Locations: 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Phase 2

Recruiting

Conditions: Splenomegaly
Myelofibrosis

Interventions: Drug: Ruxolitinib
Procedure: Allogeneic Stem Cell Transplantation
Drug: Levetiracetam
Drug: Eltrombopag
Drug: Busulfan
Drug: Romiplostim
Drug: Fludarabine phosphate
Drug: Cyclophosphamide
Drug: Mesna
Drug: Tacrolimus

First Posted Date: 2024-04-03

Last Posted Date: 2024-11-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT06345495

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Phase 1

Recruiting

Conditions: Gynecologic Cancer
Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: FT536
Drug: Fludarabine
Drug: CY

First Posted Date: 2024-04-02

Last Posted Date: 2024-07-17

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 33

Registration Number: NCT06342986

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Phase 1

Recruiting

Conditions: Recurrent Transformed Chronic Lymphocytic Leukemia
Refractory Diffuse Large B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Mantle Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Follicular Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Follicular Lymphoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Procedure: Echocardiography
Drug: Cyclophosphamide
Biological: EGFRt/19-28z/IL-12 CAR T-lymphocytes
Procedure: Multigated Acquisition Scan
Drug: Fludarabine Phosphate
Procedure: Leukapheresis
Procedure: Positron Emission Tomography

First Posted Date: 2024-04-02

Last Posted Date: 2024-12-11

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 54

Registration Number: NCT06343376

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Phase 1

Not yet recruiting

Conditions: Breast Cancer
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer

Interventions: Drug: AB-201
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-04-02

Last Posted Date: 2024-08-21

Lead Sponsor: GC Cell Corporation

Target Recruit Count: 48

Registration Number: NCT06341647

Locations: 🇦🇺
The Alfred Hosptial, Melbourne, Victoria, Australia
🇦🇺
Austin Hosptial, Melbourne, Victoria, Australia
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy